First-time market entry challenges: How to get it right with FSP support

For many biopharma and biotech companies, entering a new global market is a major milestone that represents years of research, development and investment. Yet despite strong clinical data and promising therapies, first-time market entries often fall short because organizations underestimate what it takes to operationalize approval. Too often, first-time entrant sponsors assume regulatory pathways are transferable across regions. In reality, each market introduces its own timelines, requirements and operational expectations. Many of these first-time entrants don’t factor in the risk associated with regulatory complexity, pharmacovigilance (PV) readiness and lack of local infrastructure.

This results in delays, compliance risks and missed opportunities that could have been avoided with the right preparation. To shift outcomes from reactive firefighting to first-time success, a proactive, expertise-driven outsourcing model, such as a functional service provider (FSP) partnership, is the solution.

The hidden risks of global market expansion

On paper, global expansion looks straightforward: prepare a dossier, submit, gain approval and launch. In practice, however, the process is far more complex and highly fragmented. Each region has distinct marketing authorization (MA) requirements, timelines and processes. Although use of the Common Technical Document (CTD) provides some harmonization, regional differences remain significant, from submission timelines to review pathways and post-approval obligations.

For first-time entrants, this complexity is amplified. Without prior experience or in-market knowledge, sponsors are more likely to misjudge what is required to achieve approval. Common failure points include:

• Missing critical submission timelines (such as pre-submission activities required months in advance in the EU).
• Misunderstanding regulatory pathways and requirements.
• Underestimating the need for PV readiness at the time of filing.
• Relying on internal teams that are not resourced for global expansion.

These challenges often lead to a reactive approach, addressing issues only after they arise. The consequences are significant, including delayed approvals that may push timelines back by months or even years, rework and resubmissions that increase costs, and compliance gaps that raise the risk of regulatory scrutiny. Less visible, but equally impactful, are the strategic consequences such as lost first-mover advantage, delayed patient access and reduced return on investment.

In their experience, PPD™ Functional Service Partnership (FSP) Pharmacovigilance solutions and PPD™ Functional Service Partnership (FSP) Regulatory Affairs solutions experts say market entry failure is rarely the result of a single misstep. More often, it is a cascade of preventable issues that compound over time. Understanding key areas of difference and preparing accordingly is vital to avoiding these challenges.

Why “one-size-fits-all” regulatory strategy doesn’t work

One of the most common pitfalls in global expansion is assuming that a regulatory strategy that works in one region will translate to another. The truth is that regulatory environments may vary widely. For example:

• United States – U.S. Food and Drug Administration (FDA): Sponsors must demonstrate that robust PV systems are in place for post-approval safety monitoring, but formal structures like a Pharmacovigilance System Master File (PSMF) are not required.
• European Union – European Medicines Agency (EMA): Highly structured processes require specific documentation, including a Qualified Person for Pharmacovigilance (QPPV), a PSMF and a risk management plan (RMP).
• Asia-Pacific (APAC): Country-specific requirements are highly variable, with some markets requiring local clinical data or unique post-marketing obligations. For example, China typically requires local pharmacokinetic, safety and efficacy data for approval, while Japan mandates early post-marketing phase vigilance (EPPV) during the first six months after launch.

Additional nuances further complicate the landscape:

• Language and documentation requirements (e.g., Japan).
• Local marketing authorization holder (MAH) structures.
• Region-specific submission formats and expectations.

The takeaway is clear: regulatory strategy must be localized, not standardized. But even when sponsors understand these differences, another critical gap often remains.

A key blind spot: PV readiness at submission

PV is frequently viewed as a post-approval responsibility, but in many regions, it is a prerequisite for submission. Regulators increasingly expect PV systems to be fully operational at the time of filing. This includes not only documented plans, but also the infrastructure, personnel and processes required to monitor and report safety data effectively.

PPD FSP Pharmacovigilance solutions experts note that critical PV requirements vary by region, but often include:

• Appointment of a QPPV (EU, UK, parts of Africa, China).
• Maintenance of a PSMF (EU, UK, China).
• Development of an RMP (EU, China).
• Established safety reporting systems (e.g., Individual Case Safety Report (ICSR) reporting to the Adverse Event Monitoring System (AEMS) formerly the FDA Adverse Event Reporting System (FAERS) in the U.S.).

Some regions require formal documentation, while others require demonstration of operational capability. In both cases, readiness must be established at filing, not planned for later, which is where many first-time entrants struggle. Building a compliant PV system requires cross-functional coordination across regulatory, safety and clinical teams, technology infrastructure, local personnel with regulatory knowledge and language capabilities, and alignment with region-specific requirements.

In some markets, PV obligations begin on the day of submission, leaving no room for delay. For organizations without existing infrastructure, building this capability from scratch is time-intensive and complex. As a result, PV readiness often becomes a gatekeeper for approval.

A smarter approach: building readiness with FSP support

According to PPD FSP Pharmacovigilance solutions and PPD FSP Regulatory Affairs solutions experts, to navigate this complexity, many sponsors are shifting toward a more strategic approach, leveraging FSP partners to build readiness early. Engaging with an FSP partner is not simply outsourcing; it is a way to embed expertise, infrastructure and scalability into critical functions like PV and regulatory affairs.

Core advantages of an established FSP arrangement include:

Local expertise
FSP partners provide access to in-country regulatory and PV professionals who understand regional requirements, cultural nuances and regulatory expectations, which is particularly important in diverse markets across APAC and emerging regions.

Speed to readiness
With pre-established systems, validated processes and trained personnel, an FSP partner may rapidly implement compliant PV infrastructure, enabling sponsors to meet submission timelines without compromising quality.

Reduced operational burden
Rather than building and maintaining complex systems internally, sponsors scale support based on their product lifecycle and geographic expansion. Importantly, FSP partners provide continuity across the product lifecycle, from clinical through post-market and future expansion, not just submission support.

PPD FSP Pharmacovigilance solutions and PPD FSP Regulatory Affairs solutions exemplify this model, offering end-to-end support from PSMF creation and maintenance to case processing, safety reporting and signal detection. With more than 30 years of experience, these solutions provide both global reach and local expertise.

Shift from reactive to proactive market entry strategy
The difference between first-time success and costly delays in global market entry is rarely the product itself, but rather the readiness behind it. Organizations that succeed take a proactive approach by planning for regulatory and PV readiness well before submission, integrating global strategy with local execution from the outset, and engaging expert support early to navigate complexity and mitigate risk.

Market entry should not be treated as another milestone. It should be treated as an operational launch that requires systems, processes and expertise to be in place from day one.

Ready to take a more strategic approach to global market entry?

By engaging experienced FSP partners early, sponsors may proactively navigate regional regulatory complexity, establish compliant PV systems, access local expertise and scalable infrastructure, and reduce operational burden associated with first-time market expansion. PPD FSP Pharmacovigilance solutions and PPD FSP Regulatory Affairs solutions build the readiness, flexibility and long-term support needed to accelerate approvals, maintain compliance and confidently enter new markets.